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Abstract
The potential for human exposure to pyrethroid pesticides has prompted pharmacodynamic and 
pharmacokinetic research to better characterize risk. This work tested the hypothesis that blood 
and brain concentrations of the pyrethroid bifenthrin are predictive of neurotoxic effects. Adult 
male Long Evans rats received a single oral dose of bifenthrin dissolved in corn oil. Using figure-
eight mazes, motor activity was measured for 1 h at 4- and 7-h following exposure to bifenthrin 
(0–16 mg/kg or 0–9 mg/kg, respectively; n = 4–8/group). Whole blood and brains were collected 
immediately following motor activity assays. Bifenthrin concentrations in blood and brain were 
quantified using HPLC/MS/MS. Bifenthrin exposure decreased motor activity from 20% to 70% 
in a dose-dependent manner at both time points. The relationship between motor activity data and 
administered dose, and blood and brain bifenthrin concentrations were described using a sigmoidal 
Emax model. The relationships between motor activity and administered dose or blood 
concentrations were different between the 4- and 7-h time points. The relationship between motor 
activity and brain concentration was not significantly different between the two time points. These 
data suggest that momentary brain concentration of bifenthrin may be a more precise dose metric 
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for predicting behavioral effects because the relationship between brain concentration and 
locomotor activity is independent of the time of exposure.
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1. Introduction
Pyrethroid insecticides are synthetic derivatives of pyrethrins, the natural insecticidal 
compounds found in the chrysanthemum Chrysanthemum cineraraefolum (Bradberry et al., 
2005). Pyrethroids are often classified into two groups based upon chemical structure and 
neurotoxicological effect. Type I pyrethroids, which lack an alpha-cyano moiety, induce in 
rats a syndrome consisting of aggressive sparring, altered sensitivity to external stimuli, and 
fine tremor progressing to whole-body tremor and prostration (T-syndrome). Type II 
pyrethroids, which contain an alpha-cyano moiety, produce in rats a syndrome that includes 
pawing, burrowing, salivation, and coarse tremors leading to choreoathetosis (CS-syndrome) 
(Verschoyle and Aldridge, 1980; Lawrence and Casida, 1982). While this classification is 
useful in characterizing these chemicals, there are a few pyrethroids that elicit neurotoxic 
signs of both syndromes (Verschoyle and Aldridge, 1980; Soderlund et al., 2002). In 
addition, this classification is based on high dose effects and may not relate to low dose 
effects of pyrethroids (Shafer et al., 2005; Soderlund et al., 2002; Wolansky and Harrill, 
2008). Regardless of classification, pyrethroids primarily act by disrupting voltage gated ion 
channels (Soderlund et al., 2002).
The neurotoxicity of pyrethroids appears to be due to parent compound. Induction of 
neurotoxicity is rapid following intracerebral administration of pyrethroids in laboratory 
animals (Lawrence and Casida, 1982; Gray and Rickard, 1982a,b). Brain concentrations of 
the pyrethroid deltamethrin correlate with neurotoxic endpoints (Rickard and Brodie, 1985; 
Anand et al., 2006; Kim et al., 2010). Rickard and Brodie (1985) also note that direct 
injection of phenoxybenzoic acid, a hydrolyzed product of deltamethrin, into rat brain was 
without neurotoxic effect.
Several studies have examined the relationship between blood or brain pyrethroid 
concentrations and their neurotoxic effects. In rats, the brain concentration of deltamethrin 
correlates with the induction of the CS-syndrome and the T-syndrome for cismethrin and 
bioresmethrin (Gray et al., 1980; Rickard and Brodie 1985; White et al., 1976). For each 
pyrethroid, a chemical specific threshold level in brain was required for the neurobehavioral 
effects (tremors for bioresmethrin and cismethrin, tremors and choreoathetosis for 
deltamethrin) to develop. These brain concentrations were approximately 3 nmol/g for 
deltamethrin, 3.5 nmol/g for cismethrin and 14.5 nmol/g for bioresmethrin. Sheets et al. 
(1994) reported brain concentrations of deltamethrin were associated with a neurotoxic 
response (acoustic startle response) and lethality in rats. More recently, Anand et al. (2006) 
and Kim et al. (2010) correlated levels of deltamethrin in blood and brain with neurotoxic 
signs measured as salivation and tremors. Overall, these data suggest that for neurotoxicity, 
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momentary brain concentration may be a useful dose metric for pyrethroids; however, these 
studies are limited in dose–response information.
In risk assessments, using a dose metric, that quantitatively describes the relationship 
between exposure, internal dose, and adverse effect can enhance the accuracy in 
extrapolation across species (Gentry et al., 2002). In this work, we tested the hypothesis that 
momentary pyrethroid blood and brain concentration correlates with behavioral changes. 
Bifenthrin, a Type I pyrethroid, was chosen as a prototype pyrethroid. Metabolites of 
pyrethroids are thought to be non-neurotoxic (Soderlund et al., 2002), therefore, blood and 
brain concentrations of bifenthrin were quantified and used as dose metrics. Motor activity 
was chosen as the behavioral endpoint because it is a low dose effect of Type I pyrethroids 
(Wolansky and Harrill, 2008). Evaluating the relationship between tissue concentration and 
behavioral effect will aid in determining if brain or blood concentrations are better 
descriptors of a “biologically effective” dose than is administered dose. With this type of 
data, more informative physiologically based pharmacokinetic and pharmacodynamic 
models can be developed and decrease uncertainties in risk assessments of pyrethroids.
2. Materials and methods
2.1. Chemicals
All chemicals were analytical grade unless otherwise specified. Bifenthrin (CAS no. 
82657-04-3,2-methyl-1, 1-biphenyl-3-yl-methyl-3-(2-chloro-3,3,3-trifluoro-1-propenyl)-2,2-
dimethyl cyclopropanecarboxylate, 98% purity), and cis- (99% purity) and trans-permethrin 
(3-phenoxybenzyl(1RS)-cis,trans-3-(2,2-dichlorovinyl)-2,2-
dimethylcyclopropanecarboxylate, 94% purity), were purchased from ChemService (West 
Chester, PA, USA) and used as analytical standards. Technical grade bifenthrin (89% purity) 
(IUPAC: 2-methyl-3-phenyl-phenyl)methyl 3-(2-chloro-3,3,3-trifluoro-prop-1-en-yl)-2,2-
dimethyl-cyclopropane-1-carboxylate; 99% + (Z)-(1R)-cis isomer), used in dosing solutions, 
was generously provided by FMC Corporation (Philadelphia, PA, USA). This grade of 
bifenthrin was used in previous rat neurobehavioral studies (Weiner et al., 2009; Wolansky 
et al., 2006, 2007). Labeled cis- and trans-permethrin (phenoxy-13C6) were purchased from 
Cambridge Isotope Laboratories (Andover, MA, USA) and used as internal and surrogate 
standards, respectively. Solvents, including acetone, hexanes (Fisher Scientific, Pittsburgh, 
PA) and methanol (VWR, West Chester, PA, USA), were pesticide grade quality.
2.2. Animals
Male Long Evans rats (Charles River Laboratories, Inc., Wilmington, MA, USA) were 
obtained at 55 – 58 days of age, and housed two per cage in standard polycarbonate hanging 
cages (45 cm × 24 cm × 20 cm) containing heat-sterilized pine shavings (Northeastern 
Products, Inc., Warrensburg, NY, USA). All animals were given a 5–9-day acclimation 
period and were maintained on a 12:12 h photoperiod (L:D, 0600:1800). Feed (Purina 5001 
Lab Chow, Barnes Supply Co., Durham, NC, USA) and tap water were provided ad libitum. 
Tap water (Durham, NC, USA) used in the animal facility was filtered through sand and 
activated charcoal, and finally rechlorinated to 4–5 ppm Cl−. Animal holding rooms were 
maintained at 22.0 ± 2.0 °C and relative humidity at 50 ± 10% in an American Association 
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for Accreditation of Laboratory Animal Care approved facility. The US EPA’s National 
Health and Environmental Effects Research Laboratory, Institutional Animal Care and Use 
Committee approved all experimental protocols in advance.
2.3. Experimental procedures
Rats (n = 4 or 8/group) were exposed by gavage to vehicle (corn oil) or bifenthrin at a 
volume of 1 ml/kg between 08:00 and 10:00 h. At 4 (dose = 0, 0.1, 1, 2, 4, 6, 8, 12, 16 
mg/kg) or 7 h (dose = 0, 0.05, 0.5, 1, 3, 4.5, 6, 9 mg/kg) post-dosing, rats were transferred to 
the testing room in individual plastic cages with pine shavings. The test room was 
maintained at the same environmental conditions as the animal facility. The use of corn oil 
as a vehicle and the 4- and 7-h time points were based on previous studies with bifenthrin 
(Wolansky et al., 2006, 2007). The dose range chosen in this study was designed to optimize 
the dose response relationships at each time point, based on pilot studies. While some of the 
doses do not overlap between the two time points, two of the doses were run in both time 
points.
2.4. Motor activity
Motor activity was measured in 16 figure-eight mazes, as modified by Wolansky et al. 
(2007). Briefly, motor activity was monitored for 1 h using 16 figure-eight mazes, each 
consisting of a series of interconnected alleys (10 cm × 10 cm) converging on a central arena 
and covered with transparent acrylic plastic. After 5 min of acclimation in the testing room, 
rats were placed into individual mazes. Horizontal and vertical activities were detected by 
eight phototransistor/photodiode pairs, equally spaced along the maze alleys at 0.5 in. above 
the floor (horizontal), and four pairs located 3.0 in. above the floor in the central arena. Each 
time a photobeam was interrupted, an activity count was registered (sampling rate = 1 kHz). 
Total activity was calculated as the sum of horizontal and vertical activity counts over the 1 
h test session. Exhaustive dose–effect studies examining eleven pyrethroids, including 
bifenthrin (Wolansky et al., 2006, 2007), indicated that there is no relevant advantage by 
using either component of general activity (i.e., horizontal or vertical movements) as an 
endpoint to describe pyrethroid actions on figure-eight maze performance. Photobeam 
calibration was checked daily prior to testing.
2.5. Tissue collection
Blood and whole brain tissue were collected from experimental animals under deep CO2-
induced anesthesia 20–25 min after the motor activity assay was completed. Blood (7–9 ml 
total) was collected by cardiac puncture, separated into 2 ml aliquots and frozen in a 
methanol/dry ice bath. Whole brains were removed, flash frozen in liquid nitrogen, and 
stored at −80°C until homogenized in a Spex CertiPrep 6850 freezer/mill apparatus 
(Metuchen, NJ, USA). Following homogenization, samples were again flash frozen and 
stored at −80°C until bifenthrin residue analysis was begun.
2.6. Tissue extraction
Aliquots of thawed blood (2 ml) and brain homogenate (300 mg) were extracted with 20:80 
acetone:hexane. Twenty-five µl of 6 µM trans-permethrin (phenoxy-13C6) in acetone was 
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added prior to extraction as a surrogate of recovery. Samples were vortexed for 10 min in 16 
mm × 100 mm culture tubes with 5 ml solvent and then centrifuged at 4000 × g for 10 min. 
The organic layer was collected. The extraction procedure was repeated, and both organic 
fractions were combined. Bifenthrin-containing organic fractions were dried under nitrogen 
and reconstituted in 1 ml hexane. Samples were then loaded onto a hexane rinsed Sep-pak 
500 mg silica solid phase extraction (SPE) columns (Waters, Inc., Milford, MA, USA). SPE 
columns were washed with 5 ml hexane and the bifenthrin eluted with 5 ml 94:6 
hexane:ethyl acetate. Column eluants were dried under a stream of nitrogen, and 
reconstituted in 1 ml 90:10 methanol:water with 25 µl of 6 µM cis-permethrin 
(phenoxy-13C6) in acetone added as an internal standard of instrument efficiency for 
LC/MS/MS for analysis. The solid phase cleanup was automated using a RapidTrace SPE 
Workstation (Hopkinton, MA, USA).
Extraction integrity was monitored by adding trans-permethrin (phenoxy-13C6) as a 
surrogate to each sample prior to extraction (see above). When recovery of the surrogate was 
within 80 – 120% of the expected value was considered acceptable and required no 
correction. Samples with surrogate recoveries above or below the acceptable range were 
reanalyzed.
2.7. Residue determination
Analysis of bifenthrin and 13C6-cis- and 13C6-trans-permethrin (the internal standard and 
surrogate, respectively) was performed using an Applied Biosystems API 4000 
HPLC/MS/MS (Foster City, CA, USA) operated with the turbo ion spray operated at 
atmospheric pressure. Positive ionization was used for all compounds and transition ion 
pairs and retention times were used to verify the identities of analytes. Samples were 
introduced with an isocratic 98:2 methanol:5 mM ammonium acetate mobile phase flowing 
at a rate of 0.4 ml/min and separated using a Zorbax 3.5 µm 3.0 mm × 150 mm C18 column 
(Agilent Technologies, Santa Clara, CA, USA).
Bifenthrin and the surrogate trans-permethrin were quantified using a five-point calibration 
curve, prepared in sample matrix, containing 13C6-cis-permethrin as an internal standard. 
Residue concentrations were determined by the ratio of internal standard response to the 
analyte response. Calibration standards ranged from 0.1 to 3000 ng/ml. However, curves 
were generally limited to two orders of magnitude. Calibration standards were made by 
adding the appropriate amount of bifenthrin to tissue extracts, cleaned and reconstituted in 1 
ml of methanol:water. The concentration of the lowest calibration standard was 0.1 ng/ml 
that corresponded to tissue concentrations of 0.05 ng/ml and 0.3 ng/g for blood and brain, 
respectively. The signal to noise ratio of this standard was approximately 20× the standard 
deviation of noise in unspiked blank matrices. The lowest calibration standard was used as 
the limit of quantitation. Tissue concentrations less than 0.05 ng/ml (blood) and below 0.33 
ng/g (brain) were not quantified.
2.8. Statistical analysis
Linear and non-linear regression analyses were used to assess the relationships between 
administered dose, blood and brain concentrations of bifenthrin and behavioral effects at the 
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different time points using GraphPad Prism version 5.02 for Windows (GraphPad Software, 
San Diego California, USA, www.graphpad.com). The level of significance was set at p < 
0.05. Linear regression analysis was used to compare the relationship between administered 
dose and blood and brain concentrations between the 4- and 7-h groups. Potential 
differences between the slopes and intercepts of these relationships between the 4- and 7-h 
groups were evaluated using a t-test. A sigmoidal Emax model was used to relate motor 
activity changes to administered dose or tissue concentrations and is given as:
The equation with the negative sign was used in the motor activity analysis. For this 
analysis, X is the dose, E0 is the estimated motor activity when X is 0, Emax is the estimated 
maximum possible decrease, b is the estimated ED50, and n is a shape parameter. When n 
equals 1, the dose–response relationship is linear. When n is less than 1 the dose–response 
relationship is supralinear. When n is greater than 1 the dose–response relationship becomes 
threshold-like. The biologically important characteristics of this function are that it has 
lower and upper extremes that are determined by the biological response independent of 
dose. In the motor activity modeling exercises, E0 was constrained at less than 130 and Emax 
was constrained at less than 100. Comparisons between the 4- and 7-h groups used an extra 
sum of squares F-test. The sigmoidal Emax model using the positive sign was fit to the 
bifenthrin blood vs. brain concentration data. In this case, E0 was set at zero, since in 
unexposed animals there is no bifenthrin in either blood or brain. Data from rats with either 
blood or brain bifenthrin concentrations below the level of detection were not included in 
the analysis.
Bifenthrin blood:brain concentration ratios were compared using a one-way ANOVA with 
dose as the independent variable for each time point. Comparison of the average blood:brain 
concentration ratios between the 4- and 7-h groups was performed using a Student’s t-test.
3. Results
3.1. Exposure–dose relationships
Linear models were used to determine the relationship between administered dose (i.e., 
exposure) and tissue concentrations (i.e., internal dose) of bifenthrin. A linear model 
significantly (p < 0.001) fit the administered dose vs. blood concentration data for both the 
4- and 7-h time points (Table 1; Fig. 1A). The linear model underestimated the blood 
concentrations in the low dose region at the 4-h time point. While a linear model fit both 
time points, the slopes were significantly different between the two time points (F1,84 = 
19.5; p < 0.0003). The slope of the 4-h group (24.9 ± 3.1; mean ± SE; n = 50) was 
approximately 5 times greater than that of the 7-h group (4.6 ± 0.8; n = 38). A linear model 
also fit the administered dose vs. brain concentrations data for both the 4- and 7-h time 
points. The slope of the relationship between administered dose and brain concentrations of 
bifenthrin was not significantly different (F1,85 =3.7; p = 0.058) between the 4- (32.8 ± 1.5) 
and 7-h (27.9 ± 1.7) time points and a single equation fits both data sets (Table 1; Fig. 
Scollon et al. Page 6













1B).Thus, the relationship between administered dose and brain concentrations of bifenthrin 
is similar for both the 4-and 7-h time points.
There were no dose-dependent differences in the brain:blood ratios of bifenthrin at 4 (F7,42 
= 1.8; p = 0.12) and 7 h (F6,37 = 1.35; p = 0.27) (Fig. 2A and B).The brain:blood ratio in the 
7-h animals was significantly higher than the 4-h group (t-test, p<0.01), 6.0 ± 3.3 vs. 2.6 ± 
1.4 (mean ± SD), respectively. The greater ratio in the 7-h group can be attributed to the 
lower blood concentrations in the rats at this time point (Fig. 1A) and similar brain 
concentrations at the two time points (Fig. 1B).
The relationship between bifenthrin brain and blood concentrations was evaluated using the 
sigmoidal Emax model. The fits of this model to the 4- and 7-h groups were significantly 
different (F3,88 = 7.6; p < 0.0001) (Table 2, Fig. 1C). The shape parameter of the model at 
the 4-h time point was close to unity, suggesting a linear relationship between blood and 
brain concentrations. At the 7-h time point, the shape parameter of the model was estimated 
at 2.1 ± 1.1, suggesting a slight non-linear relationship between blood and brain 
concentrations. These data demonstrate that the relationship between brain and blood 
concentration of bifenthrin is dependent upon the time of exposure.
3.2. Target tissue dose–effect relationships
The fit of the sigmoidal Emax model to the administered dose vs. motor activity (MA) data 
was significantly different (F4,84 = 3.8; p = 0.0068) between the 4- and 7-h groups (Table 3, 
Fig. 3A). The difference between the two time points was in the ED50, with the 4-h time 
point approximately 30 times lower than the 7-h time point (0.24 vs. 6.0, respectively). In 
addition, the shape parameter of the dose–response relationship for the 4-h group was 
approximately 3 times higher than that for the 7-h group, 2.0 vs. 0.6, respectively.
The relationship between bifenthrin blood concentrations and motor activity was also 
significantly different for the two time points (F4,87=4.7; p = 0.0019) (Table 4; Fig. 3B). The 
value of the shape parameter, n, when near unity suggests a linear relationship, while the 
shape of the dose–response relationship becomes increasingly threshold-like as n increases. 
The shape of the 4-h data was more threshold-like compared to the 7-h data based on the 
estimated shape parameter of 3.3 vs. 0.3, respectively. These data suggest that the 
relationship between bifenthrin blood concentrations and behavior is different between the 
two time points.
The sigmoidal Emax model fits to the 4- and 7-h bifenthrin brain concentration vs. motor 
activity data (Table 4; Fig. 3C) were not significantly different from each other (F4,90 = 2.0; 
p = 0.11). Therefore, the two data sets were combined and analyzed. The sigmoidal Emax 
model fit had a shape parameter of 1.47, suggesting slight non–linearity. These results 
indicate that the relationship between brain concentrations of bifenthrin and behavior is 
consistent between the two time points.
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This study demonstrates that administered dose and blood and brain concentrations of 
bifenthrin are predictors of behavioral change in rats. However, the best predictor of these 
three dose metrics is bifenthrin brain concentration, in part because within the parameters of 
the experiment (i.e., 4- and 7-h time points), it was independent of time of exposure. In 
contrast, the relationship between administered dose and blood concentrations of bifenthrin 
with motor activity are time dependent. The results suggest that momentary brain 
concentration of bifenthrin is an important dose metric in the prediction of neurotoxicity in 
rats and may be useful for cross-species extrapolations. Furthermore, these findings are 
consistent with data from other studies (Anand et al., 2006; Gray et al., 1980; Kim et al., 
2010; Rickard and Brodie 1985; Sheets et al., 1994; White et al., 1976) in which 
concentrations of parent pyrethroids were associated with behavioral effects.
In the first several hours after an oral exposure to a chemical, its concentration in blood can 
change because of the dynamics of this compartment. Concentrations of chemicals in the 
blood are sensitive to absorption, distribution and metabolic and renal clearance. Depending 
on the volatility of the chemical, pulmonary clearance may also be an important factor. 
Following the absorption and distribution phases, the concentrations of chemicals in blood is 
less dynamic. In the present study, blood bifenthrin concentration was related to 
administered dose in a time-dependent manner. The 4-and 7-h groups have different slopes 
when administered dose was used to predict blood concentration. There was a significant 
drop in blood levels, between the 4- and 7-h time points, which was likely due to the 
distribution of bifenthrin into tissues and metabolic clearance of bifenthrin.
Motor activity is a measure of acute bifenthrin toxicity. In this study, bifenthrin exposure 
produced a dose-dependent decrease in motor activity at both 4 and 7 h after treatment. This 
is consistent with previous studies that demonstrated a dose-dependent reduction in motor 
activity in rats following acute oral doses of pyrethroids such as deltamethrin, cypermethrin, 
permethrin, cismethrin, fenvalerate, and cyfluthrin (Crofton et al., 1995; Crofton and Reiter, 
1984, 1987, 1988; Gilbert et al., 1990; McDaniel and Moser, 1993; Wolansky et al., 2006). 
Bifenthrin was more potent at the 4- than at the 7-h time point and there was no difference in 
the relationship between administered dose and bifenthrin brain concentrations between the 
4- and 7-h time points. The relationship between brain concentration and decreased motor 
activity was equivalent between the two time points and indicates that brain concentrations 
are a better predictor than blood concentrations and administered dose of the acute 
behavioral effects of bifenthrin.
Several studies suggest that toxicity from pyrethroids occur when central nervous system 
pyrethroid concentrations exceed threshold quantities. Threshold estimates for deltamethrin 
from iv exposures in rats range from 100 to 500 ng/g brain tissue (Gray and Rickard, 1981, 
1982a,b). Tremors and choreoathetosis were observed in rabbits when brain levels of the 
Type II pyrethroid cypermethrin reached 0.7 ng/g (Khanna et al., 2002). Type I pyrethroids 
cismethrin and bioresmethrin, administered orally and iv to rats, were much less toxic, 
requiring 500–1200 ng/g and 5000 ng/g, respectively, for effects to be observed (Gray et al., 
1980; Gray and Rickard, 1982a; White et al., 1976). The studies examining tissue 
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concentrations and behavior focused on high dose behavioral changes such as tremors, 
choreoathetosis and salivation. According to the present study, brain bifenthrin 
concentration corresponding to a 50% decrease in motor activity was approximately 289 
ng/g (Fig. 3C). The data from the present study are consistent with earlier studies suggesting 
that higher concentrations of the Type I pyrethroids are necessary to produce behavioral 
toxicities than the Type II pyrethroids. However, as the sodium channel, the proposed target 
of the pyrethroids (Soderlund et al., 2002), is present in the central and peripheral nervous 
system, our results cannot rule out a role for an effect of bifenthrin on the peripheral nervous 
system.
This study examined the relationships between exposure (oral administration), dose (tissue 
concentration), and response (motor activity) of bifenthrin. Administered dose and blood 
and brain concentration can be used as dose metrics to estimate the effects of low dose, 
environmentally relevant, bifenthrin concentrations on motor function. In the present study 
the relationship between brain concentration and locomotor activity is independent of time. 
In contrast, the relationships between administered dose and locomotor activity and 
bifenthrin blood concentrations are different at the two time points. This suggests that 
momentary brain concentrations may be a better predictor of the behavioral toxicity of 
bifenthrin than are blood concentrations and administered dose. Knowing the concentration 
of toxicant at the target site and confidently relating it to effect can result in risk assessments 
with lower uncertainties than just using administered dose.
Acknowledgments
Funding
M.J.W. held a National Research Council Research Associateship Award at the National Health and Environmental 
Research Laboratory, U.S. Environmental Protection Agency while performing this work. Intramural resources of 
the U.S. Environmental Protection Agency also provided funding.
The authors thank Janet Diliberto and Drs. Linda Birnbaum, Woodrow Setzer, Jane Ellen Simmons and William 
Mundy for their helpful comments on an earlier version of the version of this manuscript. The authors also thank 
Drs. N. Hilton and M. Weiner, FMC Corp, Princeton, NJ, for graciously providing the technical grade bifenthrin. 
The authors also thank Brenda Edwards and Heather Wheeler, for their technical assistance. The data presented in 
this publication are freely available from the corresponding author (MDV).
References
Anand SS, Kim K-B, Padilla S, Muralidhara S, Kim HJ, Fisher JW, Bruckner JV. Ontogeny of hepatic 
and plasma metabolism of deltamethrin in vitro: role of age-dependent acute neurotoxicity. Drug 
Metab. Dispos. 2006; 34:389–397. [PubMed: 16326812] 
Bradberry SM, Cage SA, Proudfoot AT, Vale JA. Poisoning due to pyrethroids. Toxicol. Rev. 2005; 
24:93–106. [PubMed: 16180929] 
Crofton KM, Kehn LS, Gilbert ME. Vehicle and route dependent effects of a pyrethroid insecticide, 
deltamethrin, on motor function in the rat. Neurotoxicol. Teratol. 1995; 17:489–495. [PubMed: 
7565495] 
Crofton KM, Reiter LW. Effects of two pyrethroid insecticides on motor activity and acoustic startle 
response in the rat. Toxicol. Appl. Pharmacol. 1984; 75:318–328. [PubMed: 6474463] 
Crofton KM, Reiter LW. Pyrethroid insecticides and the gamma-aminobutyric acid A receptor 
complex: motor activity and the acoustic startle response in the rat. J. Pharmacol. Exp. Ther. 1987; 
243:946–954. [PubMed: 2826762] 
Scollon et al. Page 9













Crofton KM, Reiter LW. The effects of Type I and II pyrethroids on motor activity and the acoustic 
startle response in the rat. Fundam. Appl. Toxicol. 1988; 10:624–634. [PubMed: 3396790] 
Gentry PR, Covington TR, Andersen ME, Clewell HJ 3rd. Application of a physiologically based 
pharmacokinetic model for isopropanol in the derivation of a reference dose and reference 
concentration. Regul. Toxicol. Pharmacol. 2002; 36:51–68. [PubMed: 12383718] 
Gilbert ME, Acheson SK, Mack CM, Crofton KM. An examination of the proconvulsant actions of 
pyrethroid insecticides using pentylenetetrazol and amygdala kindling seizure models. 
Neurotoxicology. 1990; 11:73–86. [PubMed: 2374658] 
Gray AJ, Conners TA, Hoellinger H, Nguyen–Hoang–Nam. The relationship between the 
pharmacokinetics of intravenous cismethrin and bioresmethrin and their mammalian toxicity. Pestic. 
Biochem. Physiol. 1980; 13:281–293.
Gray AJ, Rickard J. Distribution of radiolabel in rats after intravenous injection of a toxic dose of 
14C–acid-, 14C–alcohol-, or 14C–cyano-labeled deltamethrin. Pestic. Biochem. Physiol. 1981; 
16:79–85.
Gray AJ, Rickard J. Toxicity of pyrethroids to rats after direct injection into the central nervous 
system. Neurotoxicology. 1982a; 3:25–35. [PubMed: 6890187] 
Gray AJ, Rickard J. The toxicokinetics of deltamethrin in rats after intravenous administration of a 
toxic dose. Pestic. Biochem. Physiol. 1982b; 18:205–215.
Khanna RN, Gupta GSD, Anand M. Kinetics of distribution of cypermethrin in blood, brain, and 
spinal cord after a single administration to rabbits. Bull. Environ. Contam. Toxicol. 2002; 69:749–
755. [PubMed: 12375126] 
Kim KB, Anand SS, Kim HJ, White CA, Fisher JW, Tornero-Velez R, Bruckner JV. Age, dose, and 
time-dependency of plasma and tissue distribution of deltamethrin in immature rats. Toxicol. Sci. 
2010; 115:354–368. [PubMed: 20211939] 
Lawrence LJ, Casida JE. Pyrethroid toxicology: mouse intracerebral structure-activity relationships. 
Pestic. Biochem. Physiol. 1982; 18:9–14.
McDaniel KL, Moser VC. Utility of a neurobehavioral screening battery for differentiating the effects 
of two pyrethroids, permethrin and cypermethrin. Neurotoxicol. Teratol. 1993; 15:71–83. 
[PubMed: 8510610] 
Rickard J, Brodie ME. Correlation of blood and brain levels of the neurotoxic pyrethroid deltamethrin 
with the onset of symptoms in rats. Pestic. Biochem. Physiol. 1985; 23:143–156.
Shafer TJ, Meyer DA, Crofton KM. Developmental neurotoxicity of pyrethroid insecticides: critical 
review and future research needs. Environ. Health Perspect. 2005; 113:123–136. [PubMed: 
15687048] 
Sheets LP, Doherty JD, Law MW, Reiter LW, Crofton KM. Age-dependent differences in the 
susceptibility of rats to deltamethrin. Toxicol. Appl. Pharmacol. 1994; 126:186–190. [PubMed: 
8184428] 
Soderlund DM, Clark JM, Sheets LP, Mullin LS, Piccirillo VJ, Sargent D, Stevens JT, Weiner ML. 
Mechanisms of pyrethroid neurotoxicity: implications for cumulative risk assessment. Toxicology. 
2002; 171:3–59. [PubMed: 11812616] 
Verschoyle RD, Aldridge WN. Structure-activity relationships of some pyrethroids in rats. Arch 
Toxicol. 1980; 45(4):325–329. [PubMed: 7447703] 
Weiner ML, Nemec M, Sheets L, Sargent D, Breckenridge C. Comparative functional observational 
battery study of twelve commercial pyrethroid insecticides in male rats following acute oral 
exposure. Neurotoxicology. 2009; 30S:S1–S16. [PubMed: 19748519] 
White NH, Verschoyle RD, Moradian MH, Barnes JM. The relationship between brain levels of 
cismethrin and bioresmethrin in female rats and neurotoxic effects. Pestic. Biochem. Physiol. 
1976; 6:491–500.
Wolansky MJ, Gennings C, Crofton KM. Relative potencies for acute effects of pyrethroids on motor 
function in rats. Toxicol. Sci. 2006; 89:271–277. [PubMed: 16221961] 
Wolansky MJ, Harrill JA. Neurobehavioral toxicology of pyrethroid insecticides in adult animals: a 
critical review. Neurotoxicol. Teratol. 2008; 30:55–78. [PubMed: 18206347] 
Wolansky MJ, McDaniel KL, Moser VC, Crofton KM. Influence of dosing volume on the 
neurotoxicity of bifenthrin. Neurotoxicol. Teratol. 2007; 29:377–384. [PubMed: 17321720] 
Scollon et al. Page 10














The relationship between administered dose of bifenthrin and blood (A) and brain (B) 
concentrations and blood and brain concentrations (C) of bifenthrin at 4 and 7 h after the 
oral administration of chemical to male rats. Linear and non-linear models were fit to the 4-h 
(□, dashed line) and 7-h (●, dotted line) data.
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The relationship between brain/blood concentration ratios and administered dose at 4 (A) 
and 7 h (B) in rats treated orally with bifenthrin. The data are presented as a box and whisker 
format. For each dose level, data are displayed as the lowest, the lower quartile, median, 
upper quartile and largest ratio observed.
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The relationship between administered dose (A), blood (B) and brain (C) concentrations and 
motor activity at 4 and 7 h after the oral administration of bifenthrin to male rats. Non-linear 
models were fit to the 4-h (□, solid line), 7-h (●, dotted line) and combined data (solid line). 
In part (C), a single model fit all the data and is represented by a solid line.
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Table 1
Linear fits and parameter estimates of bifenthrin tissue concentration vs administered dose at 4- and 7-h post-
exposure.
Parameter Blood concentration vs. administered dose Brain concentration vs. administered dose
4 h 7 h 4 h 7 h
Slope 24.9 ± 3.1a 4.6 ± 0.8 32.8 ± 1.5 27.9 ± 1.7
Intercept −34.5 ± 23.1 4.1 ± 4.2 2.3 ± 11.3 0.2 ± 8.6
r2 0.55 0.47 0.91 0.88




Number of animals where tissue concentrations were above detection limit.
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Table 2
Non-linear fits and parameter estimates of the bifenthrin blood vs. brain concentrations data at 4- and 7-h post-
exposure.a
Parameter Bifenthrin blood vs. brain concentration
4 h 7 h
Emax 860 ± 147b 238 ± 43
nc 1.0 ± 0.2 2.1 ± 1.1




Data were fit with a sigmoidal Emax model. E0 is the concentration of bifenthrin in the brain when the blood concentration was zero. Since there 








Number of animals in which tissue concentrations were above detection limit.













Scollon et al. Page 16
Table 3
Non-linear fits and parameter estimates of the administered dose of bifenthrin vs. motor activity data.a
Parameter 4 h 7 h
E0 112 ± 7.6b 158 ± 182
Emax ≈100 ≈100
nc 2.0 ± 1.1 0.6 ± 1.8




Data were fit with a sigmoidal Emax model. E0 is the motor activity of the rats when the administered dose of bifenthrin is zero and Emax is the 








Number of animals in which tissue concentrations were above detection limit.
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Table 4
Non-linear fits and parameter estimates of the bifenthrin blood and brain concentration vs. motor activity data 
at 4 and 7 h post-exposure.a
Parameter Blood concentrations Brain concentrations
Combined data
4 h 7 h
E0 108.6 ± 4.6b 130 ± 129 106.3 ± 4.5
Emax 85.2 ± 10.5 ≈100 116.5 ± 54.2
nc 3.3 ± 1.2 0.34 ± 1.6 1.5 ± 0.6
bd 78.5 ± 8.7 15.8 ± 231 289.8 ± 186.7
r2 0.66 0.12 0.58
Ne 55 40 98
a
Data was fit with a sigmoidal Emax model. E0 was the motor activity of the rats when the tissue concentration was zero and Emax is the 








Number of animals in which tissue concentrations were above detection limit.
Toxicology. Author manuscript; available in PMC 2015 December 17.
